OSTEOPOROTIC FRACTURE RISK IN RHEUMATOID ARTHRITIS
DOI:
https://doi.org/10.22159/ijpps.2018v10i3.22751Keywords:
Rheumatoid arthritis, FRAX, Osteoporosis, Disease activity, InflammationAbstract
Objective: Osteoporosis is an extra-articular complication of rheumatoid arthritis (RA) with increased risk of fractures. FRAX is an online tool for assessing risk of osteoporotic fracture. However, the relationship between the FRAX score and disease specific risk factors has not yet been investigated in RA. Hence, we assessed 10-year fracture risk using FRAX and its relationship with disease activity score, inflammation and disease duration in RA.
Methods: 50 RA patients enrolled and recruited consecutively in a special camp organized for RA patients on the occasion of World Osteoporosis Day, 2016to estimate the osteoporotic fracture risk from Rheumatology clinic. Predicted 10-year risk of hip fracture and major osteoporotic fracture (MOF) by FRAX score without information on bone mineral density (BMD). Inflammatory disease activity measures included disease activity score of 28 joints (DAS28), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were also measured. FRAX score also estimated in 40 age and sex matched healthy controls.
Results: FRAX estimated significantly enhanced fracture risk in active RA, both for MOF (13.34±1.26%) and hip fracture (6.84±1.03%) as compared to controls for MOF (5.46±0.95%) and hip fracture (1.97±0.49%). In RA patients, MOF and hip fracture risk correlated with DAS28 and disease duration and MOF risk correlated with ESR and CRP.
Conclusion: Active RA patients, even in the absence of BMD have an increased FRAX score indicating an enhanced 10-year probability of MOF and hip fracture. Long disease duration, high disease activity and an elevated ESR and CRP are potential disease specific risk factors for osteoporotic fractures in RA.
Downloads
References
Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, et al. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther 2010;12:R154.
Priyadarsini R, Menaka A. Design and synthesis of some newer imidazolyl heterocycles as potent btk inhibitors for the treatment of rheumatoid arthritis. Int J Curr Pharm Res 2017;9:80-3.
Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996;35:309–22.
Westhovens R, Dequeker J. Rheumatoid arthritis and osteoporosis. Z Rheumatol 2000;59:33–8.
Lodder MC, Haugeberg G, Lems WF, Uhlig T, Orstavik RE, Kostense PJ, et al. Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the oslo-truro-amsterdam (OSTRA) collaborative study. Arthritis Rheum 2003;49:209-15.
Bezerra MC, Carvalho JF, Prokopowitsch AS, Pereira RM. RANK, RANKL and osteoprotegerin in the arthritic bone loss. Braz J Med Biol Res 2005;38:161-70.
Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006;79:129-37.
Stone J, Doube A, Dudson D, Wallace J. Inadequate calcium, folic acid, vitamin E, zinc, and selenium intake in rheumatoid arthritis patients: results of a dietary survey. Semin Arthritis Rheum 1997;27:180-5.
Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, et al. Rheumatoid cachexia: cytokine-driven hyper¬metabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994;93:2379-86.
Manikandan N, Arunagirinathan N, Priya K, Vijaykanth N, Rameshkumar MR, Balakrishnan S. Tumor necrosis factor-alpha level in sera of South Indian patients with rheumatoid arthritis: correlation with anti-cyclic citrullinated peptide antibody level. Asian J Pharm Clin Res 2017;10:118-20.
Beck TJ, Oreskovic TL, Stone KL, Ruff CB, Ensrud K, Nevitt MC, et al. Structural adaptation to changing skeletal load in the progression toward hip fragility: the study of osteoporotic fractures. J Bone Miner Res 2001;16:1108-19.
Kanis JA, Borgstrom F, Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int 2005;16:581–9.
Broy SB. Tanner SB on behalf of the FRAX position development conference members. official positions for FRAX: clinical regarding rheumatoid arthritis. J Clin Densitometry: Assessment Skeletal Health 2011;14:184-9.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. Rheumatoid arthritis classification criteria. Arthritis Rheum 2010;62:2569–81.
Salaffi F, Ciapetti A. Clinical disease activity assessments in rheumatoid arthritis. Int J Clin Rheumatol 2013;8:347–60.
van Staa TP, Geusens P, Bilsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3104-12.
Hooyman JR, Melton J, Nelson AM, O'Fallon WM, Riggs BL. Fractures after rheumatoid arthritis: a population-based study. Arthritis Rheum 1984;27:1353-61.
Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of oteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the oslo county rheumatoid arthritis register. Arthritis Rheum 2000;43:522–30.
Kanis JA on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK.: Printed by the University of Sheffield; 2007.
Dirven L, Van denBroek M, van Groenendael JHLM, Beus WM, Kerstens PJSM, Huizinga TW, et al. Prevalence of vertebral fractures in a disease activity steered cohort of patients with early active rheumatoid arthritis. BMC Musculoskelet Disord 2012;13:125.
Kaz H, Johnson D, Kerry S, Chinappen U, Tweed K, Patel S. Fall-related risk factors and osteoporosis in women with rheumatoid arthritis. Rheumatology (Oxford) 2004;43:1267–71.
Sozen T, Ozisik L, Basaran NC. An overview and management of osteoporosis. Eur J Rheumatol 2017;4:46–56.
Klop C, De vries F, Bijlsma JW, Leufkens HG, Welsing PM. Predicting the 10 y risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density. Ann Rheum Dis 2016;75:2095-100.
Lee JH, Sung YK, Choi CB, Cho SK, Bang SY, Choe JY, et al. The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis. BMC Musculoskelet Disord 2016;17:98.
Kvien T, Haugeberg G, Uhlig T, Falch JA, Halse JI, Lems WF, et al. Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis. Ann Rheum Dis 2000;59:805-11.
Laan RF, Buijs WC, Verbeek AL, Draad MP, Corstens FH, van de Putte LB, et al. Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis 1993;52:21-6.
Ileana MC, Nelutu MA. The relationship between physical disability, disease activity and osteoporosis in patients with rheumatoid arthritis. Arch Rheumatol 2014;29:273-9.
McLean R. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep 2009;7:134-9.
Ishii S, Cauley JA, Greendale GA, Crandall CJ, Danielson ME, Ouchi Y, et al. C-reactive protein, bone strength, and 9 y fracture risk: Data from the study of women's health across the nation (SWAN). J Bone Miner Res 2013;28:1688-98.
Cauley J, Danielson M, Boudreau R, Forrest K, Zmuda J, Pahor M, et al. Inflammatory markers and incident fracture risk in older men and women: the health aging and body composition study. J Bone Miner Res 2007;22:1088-95.
